Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

Antengene Corporation Limited announced that the results of the Phase I/II TORCH-2 study will be presented as a poster discussion during the American Society for Clinical Oncology Annual Meeting, taking place from June 2nd to 6th at the McCormick Place Convention Center in Chicago, IL.

Scroll to Top